ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 271 filers reported holding ACCELERON PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $43,922,000 | +734.4% | 350,000 | +222.6% | 0.09% | +616.7% |
| Q2 2018 | $5,264,000 | -14.2% | 108,500 | -36.0% | 0.01% | -29.4% |
| Q3 2016 | $6,134,000 | -37.2% | 169,500 | -41.0% | 0.02% | -37.0% |
| Q2 2016 | $9,769,000 | -4.5% | 287,500 | -25.8% | 0.03% | -3.6% |
| Q1 2016 | $10,226,000 | -45.9% | 387,500 | 0.0% | 0.03% | -44.0% |
| Q4 2015 | $18,895,000 | -17.4% | 387,500 | -57.8% | 0.05% | -21.9% |
| Q3 2015 | $22,884,000 | -38.4% | 919,055 | -21.8% | 0.06% | -31.2% |
| Q2 2015 | $37,177,000 | -18.6% | 1,175,000 | -2.1% | 0.09% | -16.2% |
| Q1 2015 | $45,672,000 | -33.9% | 1,200,000 | -32.3% | 0.11% | -34.3% |
| Q4 2014 | $69,053,000 | +30.7% | 1,772,406 | +1.4% | 0.17% | +29.0% |
| Q3 2014 | $52,842,000 | +2.3% | 1,747,406 | +14.9% | 0.13% | -1.5% |
| Q2 2014 | $51,657,000 | +11.6% | 1,520,666 | +13.3% | 0.13% | +5.6% |
| Q1 2014 | $46,306,000 | +122.7% | 1,342,197 | +155.7% | 0.13% | +129.1% |
| Q4 2013 | $20,790,000 | – | 525,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |